The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613

Jordi Remon, Jessica Menis, Baktiar Hasan, Aleksandra Peric, Eleonora De Maio, Silvia Novello, Martin Reck, Thierry Berghmans, Bartosz Wasag, Benjamin Besse, Rafal Dziadziuszko

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    86 Citations (Scopus)

    Résumé

    The AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients (APPLE) trial is a randomized, open-label, multicenter, 3-arm, phase II study in advanced, epidermal growth factor receptor (EGFR)-mutant and EGFR tyrosine kinase inhibitor (TKI)-naive non–small-cell lung cancer (NSCLC) patients, to evaluate the best strategy for sequencing gefitinib and osimertinib treatment. Advanced EGFR-mutant NSCLC patients, with World Health Organization performance status 0-2 who are EGFR TKI treatment-naive and eligible to receive first-line treatment with EGFR TKI will be randomized to: • Arm A: osimertinib until disease progression according to Response Evaluation Criteria In Solid Tumors 1.1 (RECIST);• Arm B: gefitinib until emergence of circulating tumor DNA (ctDNA) substitution of threonine with methionine at amino acid position 790 (T790M)-positive status and then switch to osimertinib until disease progression according to RECIST; or• Arm C: gefitinib until disease progression according to RECIST and then switch to osimertinib until second radiologic disease progression.In all arms, a plasmatic ctDNA T790M test will be performed by a central laboratory at the Medical University of Gdansk (Poland) but will be applied as a predictive marker for making treatment decisions only in arm B. The primary objective is to evaluate the best strategy for sequencing of treatment with gefitinib and osimertinib in advanced NSCLC patients with common EGFR mutations, and to understand the value of liquid biopsy for the decision-making process. The progression-free survival rate at 18 months is the primary end point of the trial. The activity of osimertinib versus gefitinib to prevent brain metastases will be evaluated.

    langue originaleAnglais
    Pages (de - à)583-588
    Nombre de pages6
    journalClinical Lung Cancer
    Volume18
    Numéro de publication5
    Les DOIs
    étatPublié - 1 sept. 2017

    Contient cette citation